Dr Steven FANG PhD MBA

Executive Director

Dr Fang is founder of Invitrocue, partner at Clearbridge Accelerator and was the Group CEO of CordLife Ltd. He has been awarded with the World Economic Forum Technology Pioneer Award, Ernst & Young Entrepreneur of the Year for New Enterprise, Spirit of Enterprise and the Asia Pacific Entrepreneurship Award’s Outstanding Entrepreneur Award.

Dr Fang has over two decades of experience in building biotechnology and life sciences companies. Dr Fang was the Group CEO of CordLife Ltd, which he founded in May 2001; the company has since grown with operations in Singapore, Hong Kong, Jakarta, Indonesia, Kolkata, India, and Australia. CordLife was listed on the Australian Stock Exchange in 2004 and spun off a separate entity in 2012, which subsequently was listed on the Singapore Stock Exchange. Prior to CordLife, Dr Fang held various management positions in Becton Dickinson, Baxter Healthcare and Sterling Pharmaceuticals (now part of GSK).


Professor Hanry YU PhD

Non-Executive Director, Scientific Mentor and Advisor

Prof Hanry Yu is a Professor of Physiology at the Yong Loo Lin School of Medicine, National University Health System (NUHS). He is also a Group Leader of Tissue Engineering at the Institute of Bioengineering and Nanotechnology, Agency for Science, Technology and Research (A*STAR); Director of the Microscopy & Cytometry core facilities in NUHS; Principal Investigator and Graduate Chair at the Mechanobiology Institute, Singapore. Since 2008, Prof. Yu has been a visiting professor of mechanical, and recently of biological engineering at the Massachusetts Institute of Technology, USA.

Prof Yu graduated with a Ph.D. in Cell Biology from Duke University, USA in 1994, and exposed to interdisciplinary environment at the European Molecular Biology Laboratory (EMBL) on a HFSP Long Term Fellowship before starting his academic career in Singapore in 1997. Prof. Yu has published 121 research articles in leading journals covering a few disciplines from cell biology, biomaterials and tissue engineering, to biomedical optics, lab chips and pharmaceutical science. He has been invited to deliver >120 plenary, keynote and invited talks, published >220 conference proceedings, 6 books and filed 42 patents with 5 licensed to companies. Prof. Yu was awarded the inaugural Young Researcher Award by the National University of Singapore in 2002, the Faculty Research Excellence Award by NUHS in 2009, and the A*STAR Scientist-Entrepreneur Award 2013. He takes pride in mentoring graduate students and national scholars who went on to develop outstanding careers in academia and industry worldwide.



Ms Jamie Khoo Gee Choo

Non-Executive Director


Ms Khoo has a Master of Business Studies and is a member of the Institute of Singapore Chartered Accountants. Ms Khoo has over 20 years’ experience in accounting and corporate finance and extensive experience in company funding,  investment evaluation, due diligence and structuring. Ms Khoo is also director of ASX listed Refresh Group Ltd., Lionhub Group Ltd., MDS Financial Group Ltd. and ONG Group Limited.


Ms Ee Ting Ng

Non-Executive Director

Ms Ng has a Bachelor of Science with Honours and over 10 years of research experience in the fields of developmental and evolutionary biology. Ms Ng specialises in a wide range of experimental techniques in molecular biology, histology, tissue culture (including stem cells), microbiology and molecular diagnostic science. Ms Ng also has expertise in laboratory management and cosmetics science formulation.


Mr Chow Yee Koh

Non-Executive Director,  and Company Secretary

Mr Koh has a Bachelor of Commerce and is a fellowship member of the Association of Chartered Certified Accountants (UK). Mr Koh has over 17 years’ experience in accounting, auditing and corporate finance. Mr Koh is also the company secretary. Mr Koh is a director of ASX listed ONQ Group Limited.



Medical and Scientific Advisor, and Clinician-Scientist

Professor Homer-Vanniasinkam is a Consultant Vascular Surgeon and Founding Professor of Surgery in the UK National Health Service. Her career in clinical, translational and basic research spans almost three decades, with a focus on cellular and molecular pathophysiology.

She has extensive experience of in vivo and in vitro models of human disease and has established a number of intra- and extra-mural collaborations in these areas.

At Invitrocue, Professor Homer provides insights in the fields of personalised medicine and/or other potential new in vitro models which could have biologically relevant clinical applications. She provides scientific inspiration to InvitroCue’s research programmes, and makes recommendations for future scientific directions for the company.


Professor Chng Wee Joo MB ChB, PhD, FRCP (UK)

Clinical Advisor

Professor Chng is the Director of the National University Cancer Institute, Singapore (NCIS).

Prof Chng obtained his medical degree from the University of Leeds, UK, and did his internal medicine residency in the United Kingdom. Fellowship training in haematology was completed in Singapore before he obtained an A*STAR international fellowship (2004) to go to the Mayo Clinic for a research fellowship in multiple myeloma genetics. His current research is very translational and involves the use of high-resolution global genomic technique to understand biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies, with the aim of improving patient’s outcome and personalizing treatment.

At Invitrocue, Prof Chng provides an updated and pragmatic view of the methodological processes and implementation considerations in the clinical adoption of in vitro experimental patient-derived models for multiple myeloma and lymphoma.


Associate Professor Narayanan Gopalakrishna lyer MBBS PhD FRCSEd

Clinical Advisor

Dr Gopal lyer is a Head and Neck surgeon in National Cancer Centre and Singapore General Hospital and a Head and Senior Consultant at SingHealth Duke- NUS Head and Neck Centre. He has extensive experience in the surgical management of head and neck cancers, as well as surgery for benign diseases in the head and neck (including thyroid, salivary gland and skin lesions). He performs complex resections and reconstructions of cancers involving the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, paranasal sinuses and neck. He is actively involved in research and leads a number of research programs that aim to determine prognostic factors in oral cancers, identifying the cause of head and neck cancers in young people and development of novel therapeutic strategies in treating these cancers.

Dr Gopal Iyer graduated from National University of Singapore (1998). He subsequently went on to complete a PhD in molecular carcinogenesis at the University of Cambridge. He trained as a General surgeon at Singapore General Hospital and then went on to two separate head and neck surgical fellowships at Sydney Head and Neck Cancer Institute at Royal Prince Alfred Hospital, Australia and Memorial Sloan-Kettering Cancer Centre, New York, USA.

At Invitrocue, Dr Gopal lyer provides insights in clinical uses and perspectives in adoption of in vitro experimental patient-derived models for head and neck cancers.


Dr Michael MCMILLIAN PhD DABT (till Year 2015)

Vice President of Scientific and Regulatory Affairs, Cell-based Business Unit

Dr McMillian is Vice President of Scientific and Regulatory Affairs at Invitrocue. He has more than two decades of experience in drug testing, in vitro and in vivo toxicology. Michael is leading InvitroCue’s overall work in relation to scientific strategy with focus on our drug testing services and expanding the applications of our proprietary tissue engineered models.

Dr McMillian was a DABT (Year 2005 – 2015) toxicologist who headed the Toxicogenomics Group in the Preclinical Mechanistic Toxicology Program at Janssen Pharmaceuticals, Inc. – a pharmaceutical company of Johnson and Johnson – for 16 years. He spearheaded the In Vitro and In Vivo Toxicology Program for prioritization of compounds. His group had taken a broad coverage approach for toxicogenomics, utilizing over 140 paradigm toxicants to predict hepatotoxicity. He has also worked on predictive in vitro models for drug development and approaches to predict idiosyncratic toxicity.

He has published more than 100 original articles, book chapters, reviews and holds several patents.



Director of Scientific Development, Cell-based Business Unit

Dr Ananthanarayanan is directly responsible for the company’s cell based assaying service business, including support of all technical or scientific pre-sales to key accounts, including the delivery and completion of key projects. Other responsibilities include having oversight of Singapore and China laboratory functions and technicians.

He holds a Bachelor of Technology in Biotechnology from the SRM Institute of Science and Technology, India and a Doctor of Philosophy degree from the National University of Singapore, Singapore. He was awarded the NGS scholarship by National University of Singapore and has been published many peer-reviewed journal and conference papers.

Dr Ananthanarayanan was a former Ph.D. student in the Laboratory of Cell and Tissue Engineering (PI: Prof Hanry Yu) where he was involved in the innovation and evaluation of the novel 3D cell culture platforms in collaboration with various pharmaceutical companies. Dr. Ananthanarayanan was also a Research Fellow at the Institute of Bioengineering and Nanotechnology, A* STAR, Singapore.



Senior Scientific Advisor

Dr. Dasgupta is a highly regarded professor in New York University School of Medicine with more than a decade of experience in cancer research and drug discovery. In March 2016, his proprietary compounds were licensed to iβeCa Therapeutics, a spin-off which is venture-funded by Allied-Bristol Life Sciences.

In 2014, Dr. Dasgupta joined the Genome Institute of Singapore, A*STAR as a Senior Investigator, where he established the Centre for High-throughput Phenomics and the Perkin Elmer-GIS Joint Centre for Precision Oncology to develop new evidence-based paradigms for the treatment of cancers. He will be contributing to our scientific development of the Onco-PDO™ personalised drug screening technology.

Dr. Dasgupta is the recipient of several national and international awards such as the Harold Weintraub award, Breast Cancer Research Foundation Concept Award (USA), NYSTEM Idea Award, ACS Research Scholar Award (USA), March of Dimes Research Grant, the NYC BioAccelerate Prize, and the Wellcome Trust International Senior Research Fellowship, amongst others.


Mr Martin BACH MBA

Vice President, Operation

Mr. Martin Bach has more than 20 years of experience directing employees in multinational companies. Mr. Bach has led these companies through start-up, survival, turnaround and growth modes. He has spent decades in the medical industries. His understanding of both domestic and international businesses and global distribution channels encompasses manufacturing, wholesale, direct sales and joint ventures. Among his significant previous roles, he served as Managing Director of a German based healthcare and medical device company. An entrepreneur by heart, he then founded his own Company with a dedicated presence in Abu Dhabi, where he gained valuable knowledge on doing business and building relationships in the UAE regions.

Mr. Bach holds a Master of Business Administration, International Marketing from the Berufsakademie in Ravensburg (Germany).


Mr Dong Dong LOU

Sales Director, China Operation

Mr. Dong Dong Lou has the knowledge of clinical medicine and clinical research. He has strong links and networks with the technological leaders, key opinion leaders in China academia, hospitals, governmental institutions, venture capital companies and biotech industry. With more than 20 years of experience directing employees in multinational companies, he is a creative thinker equally comfortable in strategic planning, business development, product launches, commercial team management, sales and marketing. He is responsible for the development of Invitrocue Biomedical Service Suzhou to drive business growth and market share in China.

Mr. Lou graduates from Suzhou Medical College (China).




Head of Pre-sales and Project Management, China Operation

Dr Sijing Xiong is a toxicologist. She was graduated from Singapore Nanyang Technological University (NTU). In her PhD studies, she investigated the potential toxicity of nanomaterials used in biomedical and cosmetic products. In 2011, she won Ian Ferguson Postgraduate Fellowship and got the chance to exchange and learn in the world leading lab in the University of California, Los Angeles (UCLA). In Prof. André Nel’s nanotoxicology lab, she learnt the high content and high throughput drug testing technology. After she came back to Singapore, she joined the Institute of Bioengineering and Nanotechnology (IBN) in Singapore Agency for Science, Technology and Research (A*STAR). In IBN, she established a whole automatic drug testing platform to accurately predict the potential nephrotoxicity of compounds in a cost and time efficient way. This platform won Lush Prize 2016 and later got collaboration chance with U.S. Environmental Protection Agency.

Dr. Xiong has 10-year experience in toxicology related work. She published 21 journal papers and has two patents about toxicity prediction method in application.